



INSIDE SYNTELLIX

THE COMPANY BEHIND GAME CHANGING INNOVATIONS

Intelligent innovations for a better life.
www.syntellix.com



“SMALL SCREW – GREAT SUCCESS.”

NEUE PRESSE HANOVER (2015)

“THIS SCREW IS A MEDICAL SENSATION.“

BILD HANOVER (2013)

“SCREWS, BIOLOGICALLY DEGRADABLE.
A SELF-DEGRADING BONE IMPLANT RECEIVES
INNOVATION AWARD.”

FRANKFURTER ALLGEMEINE SONNTAGSZEITUNG (2013)

THE IMPLANTS “CAN REDUCE RECOVERY
DOWNTIME AND SAVE SURGERY BILLS.”

CHANNEL 5 SINGAPORE (2016)



INNOVATION DRIVER AND WORLD MARKET LEADER FOR TRANSFORMABLE, METALLIC IMPLANTS!

Technological innovation driver

After fractures, bones often have to be fixed temporarily with screws, pins or plates in order to heal and regain strength and stability. So far, these implants made of steel or titanium often had to be removed in a second operation, because permanent implants can cause stress shielding, provoke inflammatory or foreign body reactions. In order to minimize these problems, absorbable, yet stable implants have become subject of extensive research.

While there were many approaches to design a material that provides both adequate mechanical and degradation properties combined with excellent biocompatibility, **Syntellix succeeded in developing a revolutionary technology: MAGNEZIX® implants hit the market as the first transformable metallic devices approved for use in humans worldwide.**

Disruptive market leader

Today, Syntellix is an international medical technology company based in Hanover enjoying dynamic growth around the globe. The company specializes in research, development and marketing of a range of innovative implants based on the new disruptive magnesium alloy MAGNEZIX®.

The devices, made from the MAGNEZIX® material, are nothing less than revolutionary – despite having all the properties and stability of a metallic implant, they are fully absorbed by the body and replaced by endogenous bone tissue.


The products have been already successfully launched in more than 25 countries worldwide under the MAGNEZIX® brand. The feedback from surgeons, patients and media has been absolutely positive. For the near future, Syntellix is in the process of increasing its product portfolio and expanding geographically into new countries across the five continents.

Summary

Headquarter	Hanover, Germany
Subsidiary	Singapore
Employees ¹	30-40
Registration highlights ¹	<ul style="list-style-type: none"> • CE approval • HSA Singapore • JFDA Jordan • MDA Malaysia • MOH Iran • MOH HTIA Israel • SFDA Saudi Arabia • TGA Australia
Entered countries ¹	25 countries
Granted approvals ¹	47 countries
Devices sold ²	27,000
Successful surgeries ²	> 10,000
MAGNEZIX® product range	<ul style="list-style-type: none"> • Compression screws (CS) • Pins • Cortical Bone Screws (CBS) • Continuous portfolio extension (2 new product categories per year)
Advantages at a glance	<ul style="list-style-type: none"> • Patient benefit: Life quality enhancing <ul style="list-style-type: none"> - Shorter convalescence time - No need for a second surgery to remove implant - Low risk of bone atrophy (no stress shielding) - Lower risk of refracture - Reduction of infection risk • Societal benefit: Money saving <ul style="list-style-type: none"> - Reduced health spendings with improved benefit • Economic benefit: Time saving <ul style="list-style-type: none"> - Less work time lost

¹Status: January 2017 ²Source: Official PMS (Post Market Surveillance) Syntellix AG, February 2017

GROWING IN NUMBERS AND ACHIEVEMENTS: SYNTELLIX DEVELOPMENT TIMELINE (2008-2016).



2015



Start market entry ROW

JAN. 2015

1.500

implants sold only 1.5 years after market entry

MAR. 2015

First surgery in Asia performed at Tan Tock Seng Hospital, Singapore



Top Innovator Award

Syntellix belongs to the most innovative companies in Germany

JUNE 2015

4.000

implants have been sold so far and are available in 16 countries worldwide

AUG. 2015

Portfolio extension

CE approval for the new dimensions of MAGNEZIX® CS

SEPT. 2015

HSA approval

MAGNEZIX® implants receive the official approval of renowned Health Science Authority (HSA) for Singapore



10.000

The 10.000th MAGNEZIX® implant has been sold

2016

FEB. 2016

First MAGNEZIX® supply agreement

MAGNEZIX® implants have become part of a special cooperation contract between ukb hospital (Unfallkrankenhaus Berlin) and health insurance company AOK

MAY 2016

First jaw surgery

University Clinic Dresden first to successfully test MAGNEZIX® for maxillo-facial surgery



JUNE 2016

Second Top Innovator Award



JULY 2016

New product MAGNEZIX® Pin receives CE approval



AUG. 2016

Follow-up study after 3 years

Excellent results demonstrate outstanding efficiency of MAGNEZIX® implants in Hallux valgus surgery

OCT. 2016

Submission MAGNEZIX® Cortical Screw (CBS)



NOV. 2016

25.000

implants sold



German Future Prize Healthcare

Syntellix receives the Future Prize by cdgw (club of health economy) for its innovative medical products

WHAT DRIVES THE COMPANY'S SUCCESS: KEY FACTORS AND FIGURES.

KNOW HOW

Syntellix is the world leader in the field of transformable metallic implants. This internal know how is completed by an outstanding competence network.

PATENTS

Syntellix holds an impressive range of patents which are important assets of an innovative and technologically driven company.

PEOPLE

Highly motivated experts who have the courage to change the world – welcome to the Syntellix team.

INNOVATIONS

Innovative research leads to innovative products: this is Syntellix' daily business.


QUALITY

In thousands of surgeries, not a single unwanted result was attributed to the MAGNEZIX® product.*

RELIABILITY

In relation to 27,000 units sold worldwide (685 received feedbacks), there were just 27 genuine clinical undesirable effects announced to us, of which only 4 had to be reported to the health authorities (BfArM/BASG). Further analysis and examinations proved that not a single reported case could be attributed to the implant itself.

0.10% – this very low rate of announced events shows that MAGNEZIX® implants are safe and that there is no inadequate risk for the clinical use of the implant in patients.



*All mentioned events seem to have been caused by the applicants' learning curve for the proper use and normal clinical course of the implant. Not a single case could be attributed to the product itself or its material.

SYNTELLIX'S MISSION "INTELLIGENT INNOVATIONS FOR A BETTER LIFE" IS BASED ON UNIQUENESS AND A GLOBAL STAND-ALONE POSITION!

UNIQUE ...

- alloy and generation process.
- product advantages: MAGNEZIX® is an innovation of global scale.
- product positioning: Syntellix is the only company worldwide which has obtained a CE approval and is No.1 in the world for transformable metallic implants.
- competence network.

To date Syntellix occupies
100 % OF THE MARKET
for approved metallic
transformable implants.



Syntellix AG

Aegidientorplatz 2a
30159 Hannover
Germany

T +49 511 270 413 50
F +49 511 270 413 79

info@syntellix.com
www.syntellix.com

Misprints and errors are reserved.